A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| BMS-180048 | BMS-180048, also know as Avitriptan Fumarate, has been found to be a5HT-1B/1D-receptor agonist that was once studied as an anti-migraine agent. Synonyms: Avitriptan Fumarate; BMS 180048; BMS-180048; BMS180048; UNII-2G25KE3954; 3-(3-(4--(5-methoxy-4-pyrimidinyl)-1-piperazinyl)propyl)-N-methyl-1H-indole-5-methanesulfonamide fumarate. Grade: 98%. CAS No. 171171-42-9. Molecular formula: C26H34N6O7S. Mole weight: 574.65. |  |
| BMS 180448 | BMS 180448 is a prototype mitochondrial ATP-sensitive K+ channel stimulant. The cardioprotective effects of BMS-180448 against I/R heart injury may result from direct activation of mitoK(ATP) channel in cardiomyocytes. In Sep 2003, Phase-II for Myocardial ischaemia in USA was discontinued. Uses: Myocardial ischaemia. Synonyms: BMS 180448; BMS-180448; BMS180448; trans-N-(4-chlorophenyl)-N'-cyano-N''-(6-cyano-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)- Guanidine. Grade: 98%. CAS No. 144264-47-1. Molecular formula: C20H18ClN5O2. Mole weight: 395.85. | |
| BMS 180680 | BMS 180680 is antibacterial activity agent of new catechol-containing monobactam. It is a cell wall inhibitor. BMS-180680 is an active compound against many species of the family Enterobacteriaceae, with MICs at which 90% of the isolates were inhibited. In Oct 2002, Phase-II for Respiratory tract infections in USA was discontinued. Uses: Respiratory tract infections. Synonyms: BMS 180680; BMS180680; BMS-180680; SQ 84,100; (2R-(2alpha,3alpha(Z)))-3-((((1-(2-Amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)methyl)-6,7-dihydroxy-2-quinoxalinecarboxylic acid. Grade: 98%. CAS No. 142654-34-0. Molecular formula: C19H17N7O10S2. Mole weight: 567.51. | |
| BMS 181101 | BMS 181101, an indole derivative, has been found to be a 5-HT receptor agonist that could be probably effective against depression and also restrain serotonin reuptake at some extent. It has already been discontinued by Bristol-Myers Squibb. Synonyms: BMS 181101; BMS181101; BMS-181101; AC1L42ZR; SCHEMBL4356376; DTXSID40163380; 5-fluoro-3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indole Dihydrochloride. Grade: 98%. CAS No. 146479-45-0. Molecular formula: C20H26Cl2FN5O. Mole weight: 442.36. | |
| BMS 181168 | This active molecular is an potential cognitive enhancer originated by Bristol-Myers Squibb. Mechanism of Action is not identified. Bmy 21502 is also a nootropic agent and it can protect rodents from ECS-induced amnesia in a step-down passive avoidance task. But clinical study for treatment of Alzheimer's disease was discontinued. Uses: Alzheimer's disease. Synonyms: Bmy 21502; Bmy21502; Bmy-21502; Bms-181168; Bms 181168; Bms181168. 1-((1-(2-(trifluoromethyl)pyrimidin-4-yl)piperidin-4-yl)methyl)pyrrolidin-2-one. Grade: 98%. CAS No. 123259-91-6. Molecular formula: C15H19F3N4O. Mole weight: 328.34. | |
| BMS-181184 | BMS-181184 is an antifungal antibiotic produced by Actinomadura sp. AB1236 in a medium containing D-serine or D-cycloserine. It has activity against pathogenic fungi such as yeast, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus and Trichophyton. Synonyms: D-Serine, N-((5-((6-deoxy-3-O-beta-D-xylopyranosyl-beta-D-galactopyranosyl)oxy)-5,6,8,13-tetrahydro-1,6,9,14-tetrahydroxy-11-methoxy-3-methyl-8,13-dioxobenzo(a)naphthacen-2-yl)carbonyl)-, (5S-trans)-. CAS No. 139272-69-8. Molecular formula: C39H41NO20. Mole weight: 843.74. | |
| BMS-181532 | BMS-181532 is an antifungal antibiotic produced by Actinomadura sp. AB1236 in a medium containing D-serine or D-cycloserine. It has activity against pathogenic fungi such as yeast, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus and Trichophyton. Synonyms: BMS 181532. CAS No. 146877-08-9. Molecular formula: C34H33NO16. Mole weight: 711.62. | |
| BMS 182264 | BMS 182264 is a bio-active chemical, but few detailed information has been published yet. Synonyms: BMS 182264; BMS-182264; BMS182264; CHEMBL19169; N-Cyano-N'-(4-cyanophenyl)-N''-1,2,2-trimethylpropylguanidine. Grade: 98%. CAS No. 127749-54-6. Molecular formula: C15H19N5. Mole weight: 269.35. | |
| BMS 182874 | BMS 182874 is an endothelin receptor antagonist used as an antihypertensive agent. Uses: Antihypertensive agents. Synonyms: 5-Ddins; BMS 182874; BMS-182874; BMS182874; CHEMBL267458; 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide. CAS No. 153042-42-3. Molecular formula: C17H19N3O3S. Mole weight: 345.417. | |
| BMS 182874 | BMS 182874 is an orallyactive, highly selective endothelin receptor ( ET A receptor) antagonist, with IC 50 value of 0.150 μM, K i of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 153042-42-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-118497. |  |
| BMS-182874 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| BMS 182874 Hydrochloride | This active molecular is a selective non-peptide Endothelin ETA receptor antagonist. It displays more than 1000-fold selectivity over ETB receptors (Ki of 48 nM for ETA receptors and >50 μM for ETB). BMS 182874 displays ET-1 inhibitory efficacy in vivo and vitro and it also inhibits ET-1-induced longitudinal muscle contraction in vitro. In 2006, BMS 182874 for coronary disorders and hypertension were discontinued in USA. Uses: Coronary disorders and hypertension. Synonyms: BMS 182874; BMS-182874; BMS182874; BMS 182874 HCl; BMS 182874 hydrochloride; 5-(dimethylamino)-N-(3,4-dimethylisoxazol-5-yl)naphthalene-1-sulfonamide hydrochloride. Grade: 98%. CAS No. 1215703-04-0. Molecular formula: C17H20ClN3O3S. Mole weight: 381.88. | |
| BMS 183920 | BMS 183920, a quinoline derivative, has been found to be an angiotensin II receptor antagonist that could have potential usage in antihypertensive study. Uses: Angiotensin ii type 1 receptor blockers. Synonyms: BMS 183920; BMS-183920; BMS183920; CHEMBL305365; 2-Cyclopropyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)oxy)-4-quinolinecarboxylic acid; 4-Quinolinecarboxylicacid, 2-cyclopropyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]oxy]-. Grade: 98%. CAS No. 153072-33-4. Molecular formula: C26H19N5O3. Mole weight: 449.47. | |
| BMS-186318 | BMS-186318 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb. Synonyms: BMS 186318; BMS-186318; BMS186318; 12-Oxa-2,6,10-triazatetradecanoic acid, 4,8-dihydroxy-13,13-dimethyl-3-((4-(2-(4-morpholinyl)-2-oxoethoxy)phenyl)methyl)-11-oxo-9-(phenylmethyl)-, 1,1-dimethylethyl ester, (3S,4R,8R,9S)-; BMS-186318 analog 19; 12-Oxa-2,6,10-triazat. Grade: 98%. CAS No. 161302-40-5. Molecular formula: C36H54N4O9. Mole weight: 686.85. | |
| BMS-186511 | BMS-186511 is a Farnesyltransferase (FT) inhibitor with potential anticancer activity. Synonyms: BMS186511; BMS 186511; ((5S,8S,11S)-8,11-diisopropyl-5-(methoxycarbonyl)-7,10,13-trioxo-2-thia-6,9,12-triazapentadecan-15-yl)((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)phosphinic acid. Grade: >98%. CAS No. 167467-53-0. Molecular formula: C26H27N5O5. Mole weight: 685.90. | |
| BMS-187071 | BMS-187071 has been found to be a HIV protease inhibitor that was once studied against HIV by Bristol-Myers Squibb. Synonyms: BMS 187071; BMS187071; BMS187071; (3-((3-((2,3,3-Trimethyl-2(S)-2-hydroxy-1-oxobutyl)amino)-2-hydroxy-4-phenylbutyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid, 1,1-dimethylethyl ester; [3-[[3-[(2,3,3-Trimethyl-2(S)-2-hydroxy-1-oxobutyl)amino]-2-hydroxy-4. Grade: 98%. CAS No. 161302-39-2. Molecular formula: C32H49N3O6. Mole weight: 571.75. | |
| BMS-187308 | BMS-187308, a sulfonamide derivative, has been found to be an endothelin-A (ETA) antagonist that was once studied about its activity against pressor effect in rats. Synonyms: BMS-187308; BMS 187308; BMS187308; UNII-7K0YU35900; CHEMBL106684; 7K0YU35900; SCHEMBL6767698; BDBM50068674; 2-[2-amino-4-(2-methylpropyl)phenyl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide. Grade: 98%. CAS No. 153624-15-8. Molecular formula: C21H25N3O3S. Mole weight: 399.51. | |
| BMS-188494 | BMS-188494 is the prodrug of BMS-187745, a squalene synthase inhibitor used as an anticholesterol drug. Synonyms: 1-[bis(2,2-dimethylpropanoyloxymethoxy)phosphoryl]-4-(3-phenoxyphenyl)butane-1-sulfonic acid; BMS-188494; BMS 188494; BMS188494; UNII-F4W2579G7P. Grade: >98%. CAS No. 191866-32-7. Molecular formula: C28H39O11PS. Mole weight: 614.645. | |
| Bms 188745 potassium salt | Bms 188745 potassium salt. Uses: Designed for use in research and industrial production. Additional or Alternative Names: (αS)-3-Phenoxy-α-phosphonobenzenebutanesulfonic Acid Tripotassium Salt. Product Category: Heterocyclic Organic Compound. CAS No. 157126-15-3. Molecular formula: C16H16K3O7PS. Mole weight: 500.63. Purity: 0.96. IUPACName: tripotassium;(1S)-4-(3-phenoxyphenyl)-1-phosphonatobutane-1-sulfonate. Canonical SMILES: C1=CC=C(C=C1)OC2=CC=CC(=C2)CCCC(P(=O)([O-])[O-])S(=O)(=O)[O-].[K+].[K+].[K+]. Product ID: ACM157126153. Alfa Chemistry ISO 9001:2015 Certified. |  |
| BMS 188745 potassium salt | BMS 188745 potassium salt. Group: Biochemicals. Alternative Names: (a-S) -3-Phenoxy-a-phosphono Benzene butanesulfonic acid tripotassium salt. Grades: Highly Purified. CAS No. 157126-15-3. Pack Sizes: 10mg. Molecular Formula: C16H16K3O7PS. US Biological Life Sciences. |  Worldwide |
| BMS-189453 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS 191011 | BMS 191011 is a potent opener of the large-conductance, Ca2+-activated potassium (maxi-K) channel. It is neuroprotectant in two distinct animal models of stroke (MCAO in the SHR rat and a normotensive model of focal stroke). Synonyms: 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-one; BMS-191011; BMS 191011; BMS191011; UNII-LW7MXS978N; Bms-a. Grade: >99 %. CAS No. 202821-81-6. Molecular formula: C16H10ClF3N3O3. Mole weight: 370.71. | |
| BMS 191011 | BMS 191011. Group: Biochemicals. Grades: Purified. CAS No. 202821-81-6. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-191011 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-191095 | BMS-191095 is an activators that has selective effects on mitochondrial ATP-sensitive potassium (mitoKATP) channels. in vitro: induces mitochondrial-depolarization and vasodilation. Synonyms: (3R,4S)-4-[4-chloro-N-(1H-imidazol-2-ylmethyl)anilino]-3-hydroxy-2,2-dimethyl-3,4-dihydrochromene-6-carbonitrileBMS-191095; BMS 191095; BMS191095CHEMBL11594SCHEMBL8896325ZINC3821976BDBM50409914. CAS No. 166095-21-2. Molecular formula: C22H21ClN4O2. Mole weight: 408.88. | |
| BMS-191095 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-192364 | BMS-192364 is a prominent and discriminating inhibitor, finding profound application in the research of cancer. Specifically designed for efficacious cancer research, this remarkable compound effectively obstructs kinases that play a crucial role in the propagation and sustenance of malignant cells. Synonyms: 2-(5-chloro-2-hydroxyphenyl)-5-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-one; BMS-192364; BMS 192364; BMS192364; UNII-1NC8D8P7QF. Grade: >98%. CAS No. 202822-21-7. Molecular formula: C15H9ClF3N3O2. Mole weight: 355.7. | |
| BMS-192548 | BMS-192548 is a neuropeptide Y (NPY) receptor binding inhibitor produced by Aspergillus niger WB2346. It also has weak cytotoxicity, with an IC50 of 240 μmol/L for murine tumor cells M-109. Synonyms: TAN-1612. CAS No. 156368-93-3. Molecular formula: C21H18O9. Mole weight: 414.36. | |
| BMS-193884 | BMS-193884, an oxazol derivative, has been found to be an endothelin A receptor antagonist and was once studied in the treatmen of heart failure. Uses: Endothelin receptor antagonists. Synonyms: BMS-193884; BMS 193884; BMS193884; 7ON53PV45J; SCHEMBL4204130; BDBM50091105; N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[4-(1,3-oxazol-2-yl)phenyl]benzenesulfonamide. Grade: 98%. CAS No. 176960-47-7. Molecular formula: C20H17N3O4S. Mole weight: 395.43. | |
| BMS 193885 | BMS 193885. Group: Biochemicals. Grades: Purified. CAS No. 679839-66-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-193885 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-193885 | BMS-193885 is a selective neuropeptide Y1 receptor antagonist (Ki=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 186185-03-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-120619. | |
| BMS-193885 | BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50=5.9nM, Ki=3.3 nM. BMS-193885 displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. Synonyms: dimethyl 4-[3-[3-[4-(3-methoxyphenyl)piperidin-1-yl]propylcarbamoylamino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; BMS 193885; 679839-66-8BMS-193885; BMS193885; BMS 193885. Grade: >98%. CAS No. 186185-03-5. Molecular formula: C33H42N4O6. Mole weight: 590.71. | |
| BMS-193885 salt | BMS-193885 is a potent and selective neuropeptide Y1 receptor antagonist with IC50=5.9nM, Ki=3.3 nM. BMS-193885 displays > 47, > 100, > 160, > 160 and > 160-fold selectivity over σ1, α1, Y2, Y4 and Y5 receptors respectively. Synonyms: BMS 193885; BMS193885; 1,4-dihydro-4-[3-[[[[3-[4-(3-methoxyphenyl)-1-piperidinyl]propyl]amino]carbonyl]amino]phenyl]-2,6-dimethyl-3,5-dimethyl ester-3,5-pyridinedicarboxylic acid. Grade: >98%. CAS No. 679839-66-8. Molecular formula: C36H48N4O9. Mole weight: 680.79. | |
| BMS-194449 | BMS-194449 was found to be a β-adrenergic receptor agonist that was once studied in antihyperglycaemics as well as obesity therapy. Synonyms: BMS-194449; BMS 194449; BMS194449; UNII-93ZDV2P17I; CHEMBL320915; 93ZDV2P17I; SCHEMBL7042103; BDBM50106794; (R)-N-(5-(2-((bis(4-(difluoromethoxy)phenyl)methyl)amino)-1-hydroxyethyl)-2-hydroxyphenyl)methanesulfonamide. Grade: 98%. CAS No. 170686-12-1. Molecular formula: C24H24F4N2O6S. Mole weight: 544.52. | |
| BMS-195270 | BMS-195270 is a robust and discriminating small molecule inhibitor, finding paramount application in the biomedical sector. Its remarkable efficacy against fibroblast growth factor receptor 4 (FGFR4) imparts exceptional potency, rendering it a formidable intervention modality for malignancies driven by FGFR4. Synonyms: 2-(5-chloro-2-hydroxyphenyl)-5-[2-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-one; BMS-195270; BMS 195270; BMS195270; UNII-20UM0T170J; CHEMBL13637; SCHEMBL5754043; 20UM0T170J. Grade: >98%. CAS No. 202822-23-9. Molecular formula: C15H9ClF3N3O2. Mole weight: 355.7. | |
| BMS 195614 | BMS 195614 is a neutral RARα selective antagonist (Ki = 2.5 nM) and exhibits no significant effect on nuclear receptor corepressor (NCoR) binding. BMS 195614 moderately decreases SMRT binding to RAR and agonist-induced coactivator (CoA) recruitment. Synonyms: 4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid; 4-({[5,5-Dimethyl-8-(3-quinolinyl)-5,6-dihydro-2-naphthalenyl]carbonyl}amino)benzoic acid; Benzoic acid, 4-[[[5,6-dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]-; BMS 614. Grade: ≥98% by HPLC. CAS No. 253310-42-8. Molecular formula: C29H24N2O3. Mole weight: 448.51. | |
| BMS 195614 | BMS 195614. Group: Biochemicals. Grades: Purified. CAS No. 253310-42-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BMS-195614 | ?97% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-196085 | BMS-196085, a sulfanilamide derivative, has been found to be a β-adrenergic receptor agonist that was once studied in obesity as well as yype 2 diabetes mellitus. Synonyms: BMS-196085; BMS 196085; BMS196085; CHEMBL322862; FM0D5L3W03; SCHEMBL7042488; BDBM50106829; UNII-FM0D5L3W03; N-[5-[(1R)-2-[[(1R)-1-[4-(difluoromethoxy)phenyl]-2-phenylethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide. Grade: 98%. CAS No. 170686-10-9. Molecular formula: C24H26F2N2O5S. Mole weight: 492.54. | |
| BMS-199264 hydrochloride | BMS-199264 hydrochloride is a novel potent inhibitor of the ATP hydrolase activity of mitochondrial F1F0 ATP synthase. Synonyms: BMS-199264 HCl. CAS No. 186180-83-6. Molecular formula: C26H32Cl2N4O4S. Mole weight: 567.53. | |
| BMS-199264 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-202 | BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC 50 of 18 nM and a K D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1675203-84-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19745. | |
| BMS-202 | BMS-202 Inhibitor. Uses: Scientific use. Product Category: T3146. CAS No. 1675203-84-5. |  |
| BMS202 hydrochloride | The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis. PD-1/PD-L1 inhibitor 2 is reported to prevent the interaction of PD-L1 with PD-1 with an IC50 value of 18 nM. Synonyms: PD-1/PD-L1 inhibitor 2 hydrochloride. Molecular formula: C25H30ClN3O3. Mole weight: 455.97. | |
| BMS 204352 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-207940 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-210285 | BMS-210285 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: BMS-210285; BMS210285; BMS 210285; UNII-WS7S13Q9RH; CHEMBL60116; WS7S13Q9RH; SCHEMBL13550990; BDBM50073046. N-[5-[(1R)-2-[[(1R)-2-(3-chlorophenyl)-1-[4-(difluoromethoxy)phenyl]ethyl]amino]-1-hydroxyethyl]-2-hydroxyphenyl]methanesulfonamide. Grade: ≥98%. CAS No. 344607-69-8. Molecular formula: C24H25ClF2N2O5S. Mole weight: 526.98. | |
| BMS-212 | BMS-212 is a potent and selective stimulator of glucokinase (GK) (EC50 = 35 nM) that is promisingly used as an antidiabetic. BMS-212 has a preference for GK in liver over GK in pancreas, of which the activation may lead to non-glucose-dependent insulin secretion. Half-life of BMS-212 is 4.2h, and oral bioavailability is 15%. Uses: Potential antidiabetic. Synonyms: BMS212; BMS 212. CAS No. 2173153-38-1. Molecular formula: C25H30N3O9PS2. Mole weight: 611.62. | |
| BMS-212122 | BMS-212122 is a benzimidazole-based analogue of the potent MTP inhibitor BMS-201038. Synonyms: 9-[4-[2,5-dimethyl-4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]benzimidazol-1-yl]butyl]-N-(2,2,2-trifluoroethyl)fluorene-9-carboxamide; BMS-212122; BMS212122; BMS 212122; UNII-0Z473OO6GB. Grade: >98%. CAS No. 194213-64-4. Molecular formula: C43H36F6N4O2. Mole weight: 754.76. | |
| BMS 214428 | BMS 214428 has antineoplastic effect. Synonyms: dimethyl 4-[3-[[N-cyano-N'-[3-(4-phenylpiperidin-1-yl)propyl]carbamimidoyl]amino]phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate; UNII-6774Z74TWN; 6774Z74TWN; BMS 214428; BMS-214428; BMS214428. Grade: >98%. CAS No. 216508-01-9. Molecular formula: C33H40N6O4. Mole weight: 584.71. | |
| BMS-214662 | BMS-214662 is a Farnesyltransferase inhibitor and a nonsedating benzodiazepine derivative with potential antineoplastic activity. BMS-214662 inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. Synonyms: BMS 214662; BMS214662; ARQ-171; ARQ 171; ARQ171; (R)-1-((1H-imidazol-5-yl)methyl)-3-benzyl-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine-7-carbonitrile. Grade: 98%. CAS No. 195987-41-8. Molecular formula: C25H23N5O2S2. Mole weight: 489.61. | |
| BMS-214662 | BMS-214662 is a farnesyl transferase inhibitor. BMS-214662 can effectively block the localization and function of Ras protein in the cell membrane by inhibiting the pro-group modification of Ras protein, thereby exerting anti-tumor activity. BMS-214662 has an IC50 value of 1.3 nM for H-Ras and 8.4 nM for K-Ras. BMS-214662 can be used to study Ras-related tumor diseases[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 195987-41-8. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-16111. | |
| BMS-214662 hydrochloride | BMS-214662, a nonsedating benzodiazepine derivative, inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction. Treatment with BMS-214662 may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. BMS-214662 may be a useful drug for treating B-CLL and, in particular, an alternative for the therapy of purine analog-resistant or relapsed B-CLL. Synonyms: (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile; 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine; ARQ171; ARQ 171; ARQ-171; BMS214662; BMS214662; BMS-214662. Grade: >98%. CAS No. 195981-08-9. Molecular formula: C25H24ClN5O2S2. Mole weight: 526.1. | |
| BMS-214662 hydrochloride | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-214662 mesylate | BMS-214662 mesylate is a potent and selective inhibitor of farnesyltransferase that induces mitochondrial apoptosis in chronic myeloid leukemia stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cβ. Uses: A potent and selective inhibitor of farnesyltransferase. Synonyms: BMS-214662 mesylate; BMS 214662 mesylate; BMS214662 mesylate; (R)-2,3,4,5-Tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-Benzodiazepine-7-carbonitrile monohydrochloride, (R)-7-Cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine mesylate. Grade: ≥98%. CAS No. 474010-58-7. Molecular formula: C25H25N5O6S3. Mole weight: 585.72. | |
| BMS-229724 | BMS-229724 is a selective tight-binding inhibitor of cytosolic phospholipase A2 (cPLA2) in that it did not inhibit secreted phospholipase A2 in vitro, nor phospholipase C and phospholipase D in cells. BMS-22972 acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. Synonyms: 4-[4-[2-[2-[bis(4-chlorophenyl)methoxy]ethylsulfonyl]ethoxy]phenyl]-1,1,1-trifluorobutan-2-one; 4-(4-(2-(2-(bis(4-chlorophenyl)methoxy)ethylsulfonyl)ethoxy)phenyl)-1,1,1-trifluoro-2-butanone; BMS-229724; BMS 229724; BMS229724; 42AD6D8ECA; SCHEMBL3304414; LS-46643; UNII-42AD6D8ECA. Grade: >98%. CAS No. 221914-85-8. Molecular formula: C27H25Cl2F3O5S. Mole weight: 589.45. | |
| BMS-243117 | BMS-243117 is a potent and selective Lck inhibitor with good cellular activity against T-cell proliferation. BMS-24311 has potential to treat diseases such as rheumatoid arthritis and asthma. Synonyms: BMS-243117; BMS 243117; BMS243117; UNII-MBE6KWV0QI; CHEMBL67237; MBE6KWV0QI; SCHEMBL6058200. 2-(tert-butylcarbamoylamino)-N-(2-chloro-6-methylphenyl)-1,3-benzothiazole-6-carboxamide; BMS-243117; UNII-MBE6KWV0QI. Grade: >98%. CAS No. 225521-80-2. Molecular formula: C20H21ClN4O2S. Mole weight: 416.92. | |
| BMS-247243 | BMS-247243 is a novel β-Lactamase inhibitor which is a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Uses: Beta-lactamase-inhibitor. Synonyms: BMS-247243; BMS 247243; BMS247243; UNII-KG8365V22L. (6R,7R)-7-[[2-[4-[(E)-3-(carboxylatomethylamino)-3-oxoprop-1-enyl]-2,5-dichlorophenyl]sulfanylacetyl]amino]-3-[[2,6-dimethyl-1-[3-(4-methylmorpholin-4-ium-4-yl)propyl]pyridin-1-ium-4-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. Grade: ≥98%. CAS No. 307316-55-8. Molecular formula: C36H41Cl2N5O8S3. Mole weight: 838.83. | |
| BMS-248360 | BMS-248360 is a first orally active generation dual action receptor antagonist. BMS-248360 antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50=8.5, ETA IC50=8.9 nM). Synonyms: 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-[(3,3-dimethyl-2-oxopyrrolidin-1-yl)methyl]phenyl]-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide; BMS-248360; BMS 248360; BMS248360; UNII-EEP77N970Y; CHEMBL11706; EEP77N970Y; SCHEMBL4764273; BDBM50117910. Grade: >98%. CAS No. 254737-87-6. Molecular formula: C36H45N5O5S. Mole weight: 659.84. | |
| BMS-248360 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS 262084 | BMS 262084 is a potent and selective azetidinone-based beta-lactam tryptase inhibitor. Synonyms: (2S,3R)-1-[4-(tert-butylcarbamoyl)piperazine-1-carbonyl]-3-[3-(diaminomethylideneamino)propyl]-4-oxoazetidine-2-carboxylic acid; BMS-262084; BMS 262084; BMS262084; CHEMBL71037; UNII-I0IR71971G; I0IR71971G; BDBM50120368; DNC004491. Grade: >98%. CAS No. 253174-92-4. Molecular formula: C18H31N7O5. Mole weight: 425.48. | |
| BMS-265246 | BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4. Synonyms: BMS265246; BMS-265246; BMS 265246. Grade: >98%. CAS No. 582315-72-8. Molecular formula: C18H17F2N3O2. Mole weight: 345.34. | |
| BMS-265246 | BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research[1][2][3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 582315-72-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15275. | |
| BMS-265246 | BMS-265246 is a potent and selective pyra-zolopyridine based inhibitor of cdk2/cyclinE, cdk1/cyclinB and cdk4/ cyclinD. Group: Biochemicals. Alternative Names: (4-Butoxy-1H-pyrazolo[3, 4-b]pyridin-5-yl) (2, 6-difluoro-4-methylphenyl) methanone. Grades: Highly Purified. CAS No. 582315-72-8. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| BMS 270394 | BMS 270394 is a nuclear retinoic acid receptor (RAR-γ) agonist. Synonyms: BMS270394; BMS-270394 ; BMS 270394; BMS 189961; BMS189961; BMS-189961; (R)-3-fluoro-4-(2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetamido)benzoic acid; 3-fluoro-4-[[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid. Grade: 99%. CAS No. 262433-54-5. Molecular formula: C23H26FNO4. Mole weight: 399.46. | |
| BMS-275183 | BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. BMS-275183 given p.o. was active in a human, hormone-dependent, prostate tumor model, CWR-22, and just as effective as anti-androgen chemotherapy. BMS-275185 is lack of evidence of clinical benefit with the occurrence of two fatal events of neutropenic sepsis. Synonyms: BMS 275183; BMS275183. CAS No. 355113-98-3. Molecular formula: C43H59NO16. Mole weight: 845.94. | |
| BMS-279700 | BMS-279700, belonging to a family of novel anilino 5-azaimidazoquinoxaline analogues, is an orally active lead candidate that blocks the production of proinflammatory cytokines (IL-2 and TNFalpha) in vivo. Synonyms: (S)-N-(2-chloro-6-methylphenyl)-2-(3-methylpiperazin-1-yl)imidazo[1,5-a]pyrido[3,2-e]pyrazin-6-amine; BMS279700; BMS 279700; BMS-279700. Grade: >98%. CAS No. 240814-54-4. Molecular formula: C21H22ClN7. Mole weight: 407.899. | |
| BMS-281384 bis-HCl | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| BMS-284640 | BMS-284640 is a Na(+)/H(+) exchanger (NHE) inhibitor developed for the treatment of cardiovascular therapies. Synonyms: BMS 284640; BMS284640; N-[(1R,3R)-3-(2,3-Dihydro-benzofuran-4-yl)-2,2-dimethyl-cyclopropanecarbonyl]-guanidine. Grade: >98%. CAS No. 230640-88-7. Molecular formula: C15H19N3O2. Mole weight: 273.33. | |
Our database is helping our users find suppliers everyday.
